Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Diagnostic monitoring for methotrexate
October 2020
SHARING OPTIONS:

WALTHAM, Mass.—Echosens has highlighted new guidelines jointly issued by the American Academy of Dermatology and the National Psoriasis Foundation regarding the safety and efficacy of commonly prescribed medications for psoriasis, including methotrexate. The immunosuppressive drug has been linked to a variety of side effects on the liver, and Echosens notes that such guidelines provide support for increased use of non-invasive assessment tools such as its VCTE (FibroScan), an elastography technology.
 
Jon Gingrich, CEO of Echosens North America, said, “The AAD/NPF guidelines add to the growing evidence that direct assessments of liver health with FibroScan—a rapid, reliable and non-invasive tool—can serve as an essential part of overall health management. We are gratified by the growing recognition that liver health assessment with FibroScan can play an important role in the effective and safe management of many chronic conditions, as evidenced by these guidelines for patients with psoriasis undergoing long-term methotrexate use.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.